These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Yin H; Betts C; Saleh AF; Ivanova GD; Lee H; Seow Y; Kim D; Gait MJ; Wood MJ Mol Ther; 2010 Apr; 18(4):819-27. PubMed ID: 20068555 [TBL] [Abstract][Full Text] [Related]
5. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Yin H; Lu Q; Wood M Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354 [TBL] [Abstract][Full Text] [Related]
6. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. Hanson B; Wood MJA; Roberts TC RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516 [TBL] [Abstract][Full Text] [Related]
7. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Echigoya Y; Yokota T Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394 [TBL] [Abstract][Full Text] [Related]
8. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Malerba A; Thorogood FC; Dickson G; Graham IR Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709 [TBL] [Abstract][Full Text] [Related]
9. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]
10. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
11. Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice. Lu-Nguyen NB; Jarmin SA; Saleh AF; Popplewell L; Gait MJ; Dickson G Mol Ther; 2015 Aug; 23(8):1341-1348. PubMed ID: 25959011 [TBL] [Abstract][Full Text] [Related]
12. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice. Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046 [TBL] [Abstract][Full Text] [Related]
13. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results. van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725 [TBL] [Abstract][Full Text] [Related]
14. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment. Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664 [TBL] [Abstract][Full Text] [Related]
16. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Sharp PS; Bye-a-Jee H; Wells DJ Mol Ther; 2011 Jan; 19(1):165-71. PubMed ID: 20924363 [TBL] [Abstract][Full Text] [Related]
17. Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy. Blain AM; Greally E; McClorey G; Manzano R; Betts CA; Godfrey C; O'Donovan L; Coursindel T; Gait MJ; Wood MJ; MacGowan GA; Straub VW PLoS One; 2018; 13(6):e0198897. PubMed ID: 29912990 [TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091 [TBL] [Abstract][Full Text] [Related]
19. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Steinhaus JP; Moulton HM; Iversen PL; Wilton SD Mol Ther; 2007 Sep; 15(9):1587-92. PubMed ID: 17579573 [TBL] [Abstract][Full Text] [Related]
20. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting. Maruyama R; Yokota T Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]